Research Reports
- Outlook
- Presentation Videos
-
-
Each Research Area
- RA1Simulation and visualization of droplet and aerosol diffusion
- RA2Use of ICT to reduce infection risk
- RA3SARS-CoV-2 testing standard and technologies
- RA4Simulation of COVID-19 spread, suppression, and resource optimization
- RA5BioMedical Countermeasures (diagnosis, biomarker discovery, virus mutation analysis)
- Open Collaboration Partners
Presentation Videos
- Research Reports
- Outlook
- Presentation Videos
-
-
Each Research Area
- RA1Simulation and visualization of droplet and aerosol diffusion
- RA2Use of ICT to reduce infection risk
- RA3SARS-CoV-2 testing standard and technologies
- RA4Simulation of COVID-19 spread, suppression, and resource optimization
- RA5BioMedical Countermeasures (diagnosis, biomarker discovery, virus mutation analysis)
- Open Collaboration Partners
Presentation Videos
These videos depict the results of simulations conducted by researchers using models designed to analyze the effectiveness of countermeasures developed as part of the Cabinet Secretariat's COVID-19 AI and Simulation Project. The results shown in the videos do not reflect the official views of the Japanese Government.
Research Area1
Indoor airflow simulation and visualization of droplets, which are necessary for improving the COVID-19 Infection Prevention Guidelines for each industrial sector
Research Area2
Use of ICT and IoT for contact reduction
Research Area3
Effective combination of PCR, antibody tests, and other tests necessary for improving test efficiency and reliability
Research Area4
Simulation and designing countermeasures against possible COVID-19 resurgence: predicting spreading of infection, estimating and verifying the effectiveness of countermeasures, and predicting demands on medical resources and optimizing their allocations
Research Area5
BioMedical Counter-measures: Analysis of CT scans for early detection and avoidance of severe illness, monitoring of patients with mild illness, prediction of risk of severe illness, understanding of the effects of viral mutation, etc. (*)
(*) Drug discovery, drug repurposing, vaccine development are handled in a separate program.